Home › Triple-Negative Breast Cancer › Delaware › Newark
Triple-Negative Breast Cancer clinical trials in Newark, DE
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Medical Oncology Hematology Consultants, Newark
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Helen F. Graham Cancer Center & Research Institute ( Site 0018), Newark
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Medical Oncology Hematology Consultants, PA, Newark
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Newark
- Non-Small Cell Lung Cancer16 studies
- Prostate Cancer10 studies
- Lung Cancer9 studies
- Colorectal Cancer9 studies
- Breast Cancer8 studies
- Metastatic Cancer7 studies
- Pancreatic Cancer6 studies
- Cancer (all types)6 studies
- Ovarian Cancer5 studies
- Stomach Cancer4 studies
- Bladder Cancer4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.